RAPT
RAPT Therapeutics Inc
Price Chart
No historical data available
Latest Quote
$58.02
+0.00 (+0.00%)
Current Price
| Previous Close | $58.02 |
| Open | $57.98 |
| Day High | $58.02 |
| Day Low | $57.98 |
| Volume | 11,066,893 |
Stock Information
| Shares Outstanding | 28.96M |
| Total Debt | $2.60M |
| Cash Equivalents | $157.34M |
| Net Income | $-105.64M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $1.68B |
| EPS (TTM) | $-11.66 |
| Exchange | NGM |
Recent Price History
No history data available. Data will be fetched automatically.
About RAPT Therapeutics Inc
RAPT Therapeutics, Inc. operates as a clinical-stage immunology-based biopharmaceutical company that focuses on the discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues. Its lead oncology drug candidate is tivumecirnon (FLX475), an oral small molecule CCR4 antagonist that is in the Phase 1/2 clinical trial to investigate as a monotherapy and in combination with pembrolizumab in patients with advanced cancer. The company was formerly known as FLX Bio, Inc. and changed its name to RAPT Therapeutics, Inc. in May 2019. RAPT Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California. RAPT Therapeutics, Inc. is a subsidiary of Bristol-Myers Squibb Company.
đ° Latest News
Is It Too Late to Buy GSK After a 46% Share Price Jump?
24/7 Wall St. âĸ 2026-03-08T22:58:04Z
GSK RAPT Acquisition Adds Food Allergy Asset To Immunology Growth Story
Simply Wall St. âĸ 2026-03-07T18:06:55Z
Assessing RAPT Therapeutics (RAPT) Valuation After A Sharp 3 Month Share Price Surge
Simply Wall St. âĸ 2026-03-01T07:10:16Z
Apogee Therapeutics Stock Up 100% as Fund Lifts Stake to $28 Million
Motley Fool âĸ 2026-02-25T20:26:18Z
This Fund Bet $20 Million on RAPT Therapeutics as Stock Surges 500% This Past Year and Buyout Offer Emerges
Motley Fool âĸ 2026-02-25T20:19:51Z
Disc Medicine Lands New $20 Million Investment as FDA Sets Up Potential Q4 Catalyst
Motley Fool âĸ 2026-02-25T20:11:16Z
GSK to buy Canada's 35Pharma for $950 million
Reuters âĸ 2026-02-25T07:27:50Z
Citi lifts GSK target price but keeps neutral stance after rally
Proactive âĸ 2026-02-09T12:15:03Z
GSK Extends RSV Reach And Adds Food Allergy Assets With RAPT Deal
Simply Wall St. âĸ 2026-01-30T02:11:09Z
Assessing RAPT Therapeutics (RAPT) Valuation After A Sharp Share Price Surge
Simply Wall St. âĸ 2026-01-23T19:10:26Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $0 | $0 | $1,527,000 | $3,813,000 |
| Operating Revenue | $0 | $0 | $1,527,000 | $3,813,000 |
| Expenses | ||||
| Total Expenses | $136,101,000 | $127,062,000 | $87,322,000 | $73,022,000 |
| Other Income Expense | $6,236,000 | $10,264,000 | $1,957,000 | $5,000 |
| Other Non Operating Income Expenses | $6,236,000 | $10,264,000 | $1,957,000 | $5,000 |
| Operating Expense | $136,101,000 | $127,062,000 | $87,322,000 | $73,022,000 |
| General And Administrative Expense | $28,884,000 | $26,060,000 | $20,240,000 | $16,037,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-129,865,000 | $-116,798,000 | $-83,838,000 | $-69,204,000 |
| Normalized Income | $-129,865,000 | $-116,798,000 | $-83,838,000 | $-69,204,000 |
| Net Income From Continuing And Discontinued Operation | $-129,865,000 | $-116,798,000 | $-83,838,000 | $-69,204,000 |
| Total Operating Income As Reported | $-136,101,000 | $-127,062,000 | $-85,795,000 | $-69,209,000 |
| Net Income Common Stockholders | $-129,865,000 | $-116,798,000 | $-83,838,000 | $-69,204,000 |
| Net Income | $-129,865,000 | $-116,798,000 | $-83,838,000 | $-69,204,000 |
| Net Income Including Noncontrolling Interests | $-129,865,000 | $-116,798,000 | $-83,838,000 | $-69,204,000 |
| Net Income Continuous Operations | $-129,865,000 | $-116,798,000 | $-83,838,000 | $-69,204,000 |
| Pretax Income | $-129,865,000 | $-116,798,000 | $-83,838,000 | $-69,204,000 |
| Operating Income | $-136,101,000 | $-127,062,000 | $-85,795,000 | $-69,209,000 |
| Per Share | ||||
| Diluted EPS | $-25.52 | $-24.40 | $-20.64 | $-20.24 |
| Basic EPS | $-25.52 | $-24.40 | $-20.64 | $-20.24 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-134,898,000 | $-125,846,000 | $-84,748,000 | $-68,213,000 |
| Reconciled Depreciation | $1,203,000 | $1,216,000 | $1,047,000 | $996,000 |
| EBITDA (Bullshit earnings) | $-134,898,000 | $-125,846,000 | $-84,748,000 | $-68,213,000 |
| EBIT | $-136,101,000 | $-127,062,000 | $-85,795,000 | $-69,209,000 |
| Diluted Average Shares | $5,095,142 | $4,792,270 | $4,067,550 | $3,423,790 |
| Basic Average Shares | $5,095,142 | $4,792,270 | $4,067,550 | $3,423,790 |
| Diluted NI Availto Com Stockholders | $-129,865,000 | $-116,798,000 | $-83,838,000 | $-69,204,000 |
| Research And Development | $107,217,000 | $101,002,000 | $67,082,000 | $56,985,000 |
| Selling General And Administration | $28,884,000 | $26,060,000 | $20,240,000 | $16,037,000 |
| Other Gand A | $28,884,000 | $26,060,000 | $20,240,000 | $16,037,000 |
| Tax Provision | - | - | - | $0 |
Fetched: 2026-03-02
Balance Sheet (Annual)
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $189,904,000 | $147,035,000 | $245,166,000 | $186,380,000 |
| Total Assets | $240,325,000 | $173,329,000 | $266,209,000 | $198,636,000 |
| Total Non Current Assets | $5,088,000 | $11,547,000 | $13,515,000 | $5,663,000 |
| Other Non Current Assets | $389,000 | $3,871,000 | $4,036,000 | $2,922,000 |
| Current Assets | $235,236,000 | $161,782,000 | $252,694,000 | $192,973,000 |
| Other Current Assets | $4,181,000 | $2,920,000 | $3,626,000 | $3,319,000 |
| Cash Cash Equivalents And Short Term Investments | $231,055,000 | $158,862,000 | $249,068,000 | $189,654,000 |
| Cash And Cash Equivalents | $169,735,000 | $47,478,000 | $38,946,000 | $24,027,000 |
| Prepaid Assets | - | - | - | $3,319,000 |
| Debt | ||||
| Total Debt | $4,492,000 | $6,906,000 | $8,990,000 | $0 |
| Long Term Debt And Capital Lease Obligation | $2,070,000 | $4,458,000 | $6,819,000 | $0 |
| Current Debt And Capital Lease Obligation | $2,422,000 | $2,448,000 | $2,171,000 | - |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $50,421,000 | $26,294,000 | $21,043,000 | $12,256,000 |
| Total Non Current Liabilities Net Minority Interest | $2,070,000 | $4,458,000 | $6,819,000 | $2,661,000 |
| Current Liabilities | $48,351,000 | $21,836,000 | $14,224,000 | $9,595,000 |
| Other Current Liabilities | $57,000 | $109,000 | $32,000 | $254,000 |
| Payables And Accrued Expenses | $39,149,000 | $12,976,000 | $7,403,000 | $4,673,000 |
| Payables | $36,275,000 | $5,176,000 | $3,365,000 | $1,999,000 |
| Other Payable | $35,000,000 | - | - | - |
| Accounts Payable | $1,275,000 | $5,176,000 | $3,365,000 | $1,999,000 |
| Non Current Deferred Liabilities | - | - | $0 | $2,661,000 |
| Current Deferred Liabilities | - | - | $0 | $1,016,000 |
| Equity | ||||
| Common Stock Equity | $189,904,000 | $147,035,000 | $245,166,000 | $186,380,000 |
| Total Equity Gross Minority Interest | $189,904,000 | $147,035,000 | $245,166,000 | $186,380,000 |
| Stockholders Equity | $189,904,000 | $147,035,000 | $245,166,000 | $186,380,000 |
| Gains Losses Not Affecting Retained Earnings | $50,000 | $103,000 | $-26,000 | $-206,000 |
| Other Equity Adjustments | $50,000 | $103,000 | $-26,000 | $-206,000 |
| Retained Earnings | $-614,547,000 | $-484,682,000 | $-367,884,000 | $-284,046,000 |
| Other | ||||
| Ordinary Shares Number | $16,500,853 | $4,299,789 | $4,281,789 | $3,694,389 |
| Share Issued | $16,500,853 | $4,299,789 | $4,281,789 | $3,694,389 |
| Tangible Book Value | $189,904,000 | $147,035,000 | $245,166,000 | $186,380,000 |
| Invested Capital | $189,904,000 | $147,035,000 | $245,166,000 | $186,380,000 |
| Working Capital | $186,885,000 | $139,946,000 | $238,470,000 | $183,378,000 |
| Capital Lease Obligations | $4,492,000 | $6,906,000 | $8,990,000 | $0 |
| Total Capitalization | $189,904,000 | $147,035,000 | $245,166,000 | $186,380,000 |
| Additional Paid In Capital | $804,388,000 | $631,611,000 | $613,073,000 | $470,629,000 |
| Capital Stock | $13,000 | $3,000 | $3,000 | $3,000 |
| Common Stock | $13,000 | $3,000 | $3,000 | $3,000 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Long Term Capital Lease Obligation | $2,070,000 | $4,458,000 | $6,819,000 | $0 |
| Current Capital Lease Obligation | $2,422,000 | $2,448,000 | $2,171,000 | $0 |
| Pensionand Other Post Retirement Benefit Plans Current | $6,723,000 | $6,303,000 | $4,618,000 | $3,652,000 |
| Current Accrued Expenses | $2,874,000 | $7,800,000 | $4,038,000 | $2,674,000 |
| Net PPE | $4,699,000 | $7,676,000 | $9,479,000 | $2,741,000 |
| Accumulated Depreciation | $-10,081,000 | $-9,367,000 | $-8,249,000 | $-7,684,000 |
| Gross PPE | $14,780,000 | $17,043,000 | $17,728,000 | $10,425,000 |
| Leases | $3,295,000 | $3,295,000 | $3,295,000 | $3,295,000 |
| Other Properties | $10,368,000 | $12,627,000 | $13,498,000 | $6,291,000 |
| Machinery Furniture Equipment | $1,117,000 | $1,121,000 | $935,000 | $839,000 |
| Properties | $0 | $0 | $0 | $0 |
| Other Short Term Investments | $61,320,000 | $111,384,000 | $210,122,000 | $165,627,000 |
| Non Current Deferred Revenue | - | - | $0 | $511,000 |
| Current Deferred Revenue | - | - | $0 | $1,016,000 |
Fetched: 2026-03-02
Cash Flow Statement (Annual)
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-83,419,000 | $-98,173,000 | $-71,616,000 | $-61,781,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-83,297,000 | $-97,048,000 | $-70,771,000 | $-61,026,000 |
| Cash Flow From Continuing Operating Activities | $-83,297,000 | $-97,048,000 | $-70,771,000 | $-61,026,000 |
| Operating Gains Losses | - | $-655,000 | $627,000 | $258,000 |
| Investing Activities | ||||
| Capital Expenditure | $-122,000 | $-1,125,000 | $-845,000 | $-755,000 |
| Investing Cash Flow | $52,702,000 | $104,133,000 | $-45,490,000 | $-81,347,000 |
| Cash Flow From Continuing Investing Activities | $52,702,000 | $104,133,000 | $-45,490,000 | $-81,347,000 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $152,007,000 | $0 | $129,788,000 | $139,460,000 |
| Financing Cash Flow | $152,852,000 | $1,447,000 | $131,180,000 | $141,482,000 |
| Cash Flow From Continuing Financing Activities | $152,852,000 | $1,447,000 | $131,180,000 | $141,482,000 |
| Net Common Stock Issuance | $152,007,000 | $0 | $129,788,000 | $139,460,000 |
| Common Stock Issuance | $152,007,000 | $0 | $129,788,000 | $139,460,000 |
| Other | ||||
| End Cash Position | $169,735,000 | $47,478,000 | $38,946,000 | $24,027,000 |
| Beginning Cash Position | $47,478,000 | $38,946,000 | $24,027,000 | $24,918,000 |
| Changes In Cash | $122,257,000 | $8,532,000 | $14,919,000 | $-891,000 |
| Proceeds From Stock Option Exercised | $845,000 | $1,447,000 | $1,392,000 | $2,022,000 |
| Net Investment Purchase And Sale | $52,824,000 | $105,258,000 | $-44,645,000 | $-80,592,000 |
| Sale Of Investment | $135,042,000 | $266,755,000 | $146,211,000 | $84,385,000 |
| Purchase Of Investment | $-82,218,000 | $-161,497,000 | $-190,856,000 | $-164,977,000 |
| Net PPE Purchase And Sale | $-122,000 | $-1,125,000 | $-845,000 | $-755,000 |
| Purchase Of PPE | $-122,000 | $-1,125,000 | $-845,000 | $-755,000 |
| Change In Working Capital | $25,907,000 | $5,499,000 | $-1,335,000 | $-4,298,000 |
| Change In Other Current Liabilities | $-2,855,000 | $-2,707,000 | $-2,097,000 | $0 |
| Change In Payables And Accrued Expense | $26,541,000 | $7,335,000 | $3,710,000 | $933,000 |
| Change In Payable | $26,541,000 | $7,335,000 | $3,710,000 | $933,000 |
| Change In Account Payable | $-8,459,000 | $7,335,000 | $3,710,000 | $933,000 |
| Change In Prepaid Assets | $2,221,000 | $871,000 | $-1,421,000 | $-1,764,000 |
| Other Non Cash Items | $2,336,000 | $2,335,000 | $1,760,000 | - |
| Stock Based Compensation | $19,935,000 | $17,091,000 | $11,264,000 | $9,952,000 |
| Amortization Of Securities | $-2,813,000 | $-5,736,000 | $-296,000 | $1,270,000 |
| Depreciation Amortization Depletion | $1,203,000 | $1,216,000 | $1,047,000 | $996,000 |
| Depreciation And Amortization | $1,203,000 | $1,216,000 | $1,047,000 | $996,000 |
| Net Foreign Currency Exchange Gain Loss | $0 | $-655,000 | $627,000 | $258,000 |
| Net Income From Continuing Operations | $-129,865,000 | $-116,798,000 | $-83,838,000 | $-69,204,000 |
| Sale Of PPE | - | - | $0 | $0 |
| Change In Other Working Capital | - | - | $-1,527,000 | $-3,467,000 |
| Income Tax Paid Supplemental Data | - | - | - | $0 |
| Gain Loss On Sale Of PPE | - | - | - | $0 |
Fetched: 2026-03-02